Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1983 Jul;15(2):78–83. doi: 10.1007/BF00199694

Thymosin α1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays

Yukio Umeda 1, Atsuko Sakamoto 1, Junko Nakamura 1, Hideo Ishitsuka 1,, Yasuo Yagi 1
PMCID: PMC11039271  PMID: 6553515

Abstract

The effect of thymosin against tumor progression was examined in mice immunosuppressed by cytostatics or X-ray irradiation. When pretreated with cytostatic agents, such as 5-fluorouracil (5-FU) or BCNU, or by X-ray, and then inoculated with P388 or L1210 leukemias, mice died rapidly within a few days. In these systems, thymosin α1 given concomitantly with the cytostatic agents or after X-irradiation prevented rapid death and extended survival, although the mice eventually died with leukemia like normal mice inoculated with cells of the same tumor. Rapid death in the 5-FU-treated mice was also prevented by adoptive transfer of spleen cells from the donor mice if these had been treated with 5-FU plus thymosin α1, but not if they had received 5-FU alone. However, the restorative activity of the donor spleen cells was abrogated by treatment with anti-asialo GM1, but not by treatment with anti-Thy 1 or anti-mouse Ig serum, suggesting that the effector cells in the spleen are NK cells. In fact, thymosin α1, when given concomitantly with 5-FU or after X-irradiation, maintained the NK activity of spleen, which was damaged by treatment with 5-FU or X-irradiation alone. The present study indicates that thymosin α1 exerts a preventive activity against progression of leukemias at least in part through an effect on NK cells or their progenitor cells.

Keywords: Leukemia, Spleen Cell, Restorative Activity, Adoptive Transfer, BCNU

References

  • 1.Ahmed A, Smith AH, Wong DM, Thurman GB, Goldstein AL, Sell KW. In vitro induction of Lyt surface markers on precursor cells incubated with thymosin polypeptides. Cancer Treat Rep. 1978;62:1739. [PubMed] [Google Scholar]
  • 2.Chirigos MA. In vitro and in vivo studies with thymosin. In: Chirigos MA, editor. Immune modulation and control of neoplasia by adjuvant therapy. New York: Raven Press; 1978. p. 305. [Google Scholar]
  • 3.Garibjanian BT, Johnson RK, Kline I, Vadlamudi S, Gang M, Venditti JM, Goldin A. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors. Cancer Treat Rep. 1978;60:1317. [PubMed] [Google Scholar]
  • 4.Goldschneider I, Ahmed A, Bollum FJ, Goldstein AL. Induction of terminal deoxynucleotidyl transferase and Lyt antigens with thymosin: Identification of multiple subsets of prothymocytes in mouse bone marrow and spleen. Proc Natl Acad Sci USA. 1981;78:2469. doi: 10.1073/pnas.78.4.2469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Goldstein AL, Low TLK, McAdoo M, McClure J, Thurman GB, Rossio J, Lai C-Y, Chang D, Wang S-S, Harvey C, Ramel AH, Meienhofer J. Thymosin α1: Isolation and sequence analysis of immunologically active polypeptide. Proc Natl Acad Sci USA. 1977;74:725. doi: 10.1073/pnas.74.2.725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Good RA. Relations between immunity and malignancy. Proc Natl Acad Sci USA. 1972;69:1026. doi: 10.1073/pnas.69.4.1026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gorelik E, Segal S, Feldman M. Control of lung metastasis progression in mice: Role of growth kinetics of 3LL Lewis lung carcinoma and host immune reactivity. J Natl Cancer Inst. 1980;65:1257. [PubMed] [Google Scholar]
  • 8.Hanna N, Burton RC. Definitive evidence that natural killer cells inhibit experimental tumor metastasis in vivo. J Immunol. 1981;127:1754. [PubMed] [Google Scholar]
  • 9.Ishitsuka H, Umeda Y, Nakamura J, Yagi Y (1982a) Protective activity of thymosin against opportunistic infections in animal models. Cancer Immunol Immunother [DOI] [PMC free article] [PubMed]
  • 10.Ishitsuka H, Umeda Y, Sakamoto A, Yagi Y. Protective activity of thymosin α1 against tumor progression in mice immunosuppressed. Proceedings of International Symposium on Biological Response Modifiers in Human Oncology and Immunology. New York: Plenum Press; 1982. [Google Scholar]
  • 11.Kärre K, Klein GO, Kiessling R, Klein G, Roder JC. Low natural in vivo resistance to syngeneic leukemias in natural killer-deficient mice. Nature. 1980;284:624. doi: 10.1038/284624a0. [DOI] [PubMed] [Google Scholar]
  • 12.Kasai M, Iwamori M, Nagai Y, Okumura K, Tada T. A glycolipid on the surface of mouse natural killer cells. Eur J Immunol. 1980;10:175. doi: 10.1002/eji.1830100304. [DOI] [PubMed] [Google Scholar]
  • 13.Laia PK. Effects of tumor bearing on the dynamics of host hematopoietic cells. Cancer Treat Rep. 1978;60:1781. [PubMed] [Google Scholar]
  • 14.Lipson SD, Chretien PB, Makuch R, Kenady DE, Cohen MH. Thymosin immunotherapy in patients with small cell carcinoma of the lung: Correlation of in vitro studies with clinical course. Cancer. 1979;43:863. doi: 10.1002/1097-0142(197903)43:3<863::aid-cncr2820430313>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  • 15.Mantovani A, Candiani P, Luini W, Salmona M, Spreafico F, Garattini S. Effect of chemotherapeutic agents on host defense mechanism: Its possible relevance for the antitumoral activity of these drugs. In: Ferrone S, Corini S, Herberman RB, Reisfeld RA, editors. Current trends in tumor immunology. New York: Garland STPM Press; 1980. p. 139. [Google Scholar]
  • 16.Moore M, Williams DE. Contribution of host immunity to cyclophosphamide therapy of a chemically induced murine sarcoma. Int J Cancer. 1973;11:358. doi: 10.1002/ijc.2910110213. [DOI] [PubMed] [Google Scholar]
  • 17.Nair MPN, Schwartz SA, Fernandes G, Pahwa R, Ikegami S, Good RA. Suppression of natural killer (NK) cell activity of spleen cells by thymocytes. Cell Immunol. 1981;58:9. doi: 10.1016/0008-8749(81)90144-1. [DOI] [PubMed] [Google Scholar]
  • 18.Radov LA, Haskill JS, Korn JH. Host immune protection of drug responses to a murine mammary adenocarcinoma. Int J Cancer. 1976;17:773. doi: 10.1002/ijc.2910170613. [DOI] [PubMed] [Google Scholar]
  • 19.Riccardi C, Barlozzari T, Santoni A, Herberman R, Cesarini C. Transfer to cyclophosphamide-treated mice of natural killer (NK) cells and in vivo natural reactivity against tumor. J Immunol. 1981;126:1284. [PubMed] [Google Scholar]
  • 20.Schwartz HS, Grindey GB. Adriamycin and daunomycin: A comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res. 1973;33:1837. [PubMed] [Google Scholar]
  • 21.Talmadge JE, Meyers KM, Prieur DJ, Starkey JR. Role of NK cells in tumor growth and metastasis in beige mice. Nature. 1980;284:622. doi: 10.1038/284622a0. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES